84680-54-6

Basic information

• Product Name: ENALAPRILAT DIHYDRATE
• Synonyms: (S)-1-[N-[1-(CARBOXY)-3-PHENYLPROPYL]-L-ALANYL]-L-PROLINE, DIHYDRATE;MK-422;ENALAPRILAT DIHYDRATE;ENALAPRILATE;Enalaprilate USP25;ENALAPRILAT USP;Enalaprilat (300 mg);Enalaprilic Acid Dihydrate
• CAS NO: 84680-54-6
• Molecular Formula: C18H28N2O7
• Molecular Weight: 384.42
• EINECS: 278-459-3
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Inhibitors
• Mol File: 84680-54-6.mol

Chemical Properties

• Melting Point: 151-159°C
• Boiling Point: 563.5 °C at 760 mmHg
• Flash Point: 294.6 °C
• Appearance: /
• Density: 1.286g/cm³
• Vapor Pressure: 2.71E-15mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: -20°C Freezer
• Solubility: H2O: soluble14mg/mL at 60°C (warming for 5 minutes)
• CAS DataBase Reference: ENALAPRILAT DIHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: ENALAPRILAT DIHYDRATE(84680-54-6)
• EPA Substance Registry System: ENALAPRILAT DIHYDRATE(84680-54-6)

Safety Data

• WGK Germany: 3
• RTECS: TW3590600
• Hazardous Substances Data: 84680-54-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ENALAPRILAT DIHYDRATE is used as an active metabolite for the management of hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathies. It functions as a nonsulfhydryl dipeptide angiotensin-converting enzyme (ACE) inhibitor, helping to regulate blood pressure and improve cardiovascular health.
Used in Research and Development:
ENALAPRILAT DIHYDRATE is used as an impurity standard in the development and quality control of enalapril-related pharmaceutical products. It helps ensure the purity, potency, and safety of enalapril-based medications, contributing to the overall efficacy and reliability of these treatments.

Biochem/physiol Actions

Enalapril, the ethyl ester of?enalaprilat exhibits slight pharmacological activity until it is hydrolyzed in the liver to?enalaprilat. Enalaprilat, a IV form of an angiotensin-converting-enzyme inhibitor (ACE) prevents the transformation of angiotensin I to angiotensin II, a potent vasoconstrictor.

InChI:InChI=1/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14+,15+/m0/s1

Upstream product

• 75847-73-3 enalapril 
• 4363-35-3 Dihydroxy-styryl-boran 
• 6000-59-5 glyoxalic acid monohydrate 

Relevant articles and documents

Method for the synthesis of amines and amino acids with organoboron derivatives

Amines and amino acids are prepared by reacting an amine, a carbonyl derivative, and an organoboron compound under mild conditions.

Prodrug derivatives of carboxylic acid drugs

Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R1 and R2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R1 and R2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.